ARTICLE | Politics, Policy & Law
COVID-19 mAb developers with ties to China excluded from Warp Speed
NIH is testing mAbs from Vir and Brii, but the U.S. government won’t fund the products
December 19, 2020 4:37 AM UTC
Updated on Dec 20, 2020 at 7:49 PM UTC
The Trump administration’s America First policies, especially its reluctance to support life sciences companies with ties to China, may be slowing the development of medicines that could treat or prevent COVID-19.
Two biotechs focused on infectious diseases, Vir Biotechnology Inc. (NASDAQ:VIR) and Brii Biosciences, have persuaded NIH that their mAbs may benefit patients hospitalized with COVID-19, but have had far less success in overcoming the U.S. government’s resistance to funding companies with links to China. ...